AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE

N/A

Manufactured by Aurobindo Pharma Limited

48 FDA adverse event reports analyzed

Last updated: 2026-04-15

About AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE

AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE include ASTHENIA, BACK PAIN, COUGH, DIZZINESS, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE.

Top Adverse Reactions

ASTHENIA2 reports
BACK PAIN2 reports
COUGH2 reports
DIZZINESS2 reports
FATIGUE2 reports
ADRENOCORTICAL INSUFFICIENCY ACUTE1 reports
ALOPECIA1 reports
ARTHRALGIA1 reports
CYSTITIS1 reports
DEEP VEIN THROMBOSIS1 reports
DRUG INEFFECTIVE1 reports
FAECES HARD1 reports
FALL1 reports
FEMUR FRACTURE1 reports
HYPERKERATOSIS1 reports
INCREASED TENDENCY TO BRUISE1 reports
INJECTION SITE BRUISING1 reports
INSOMNIA1 reports
INTESTINAL CYST1 reports
MENSTRUAL DISORDER1 reports
METASTASES TO BONE1 reports
MUSCULOSKELETAL STIFFNESS1 reports
MYALGIA1 reports
NASOPHARYNGITIS1 reports
NECK PAIN1 reports
NEOPLASM MALIGNANT1 reports
OFF LABEL USE1 reports
OPEN REDUCTION OF FRACTURE1 reports
OROPHARYNGEAL PAIN1 reports
OSTEOLYSIS1 reports
PAIN1 reports
PANCREATITIS1 reports
PNEUMONIA1 reports
POST PROCEDURAL COMPLICATION1 reports
PULMONARY EMBOLISM1 reports
RESTLESSNESS1 reports
SINUSITIS1 reports
SKIN PAPILLOMA1 reports
SQUAMOUS CELL CARCINOMA1 reports
STRESS FRACTURE1 reports
THERAPEUTIC RESPONSE DECREASED1 reports
TOOTHACHE1 reports
UNDERDOSE1 reports

Report Outcomes

Out of 8 classified reports for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE:

Serious 87.5%Non-Serious 12.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female5 (71.4%)
Male2 (28.6%)

Reports by Age

Age 331 reports
Age 471 reports
Age 521 reports
Age 781 reports
Age 801 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE?

This profile reflects 48 FDA FAERS reports that mention AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE?

Frequently reported terms in FAERS include ASTHENIA, BACK PAIN, COUGH, DIZZINESS, FATIGUE, ADRENOCORTICAL INSUFFICIENCY ACUTE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE?

Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.